Eduardo Candelario-Jalil

Eduardo Candelario-Jalil,

Associate Professor, Graduate Co-Coordinator Neuroscience Graduate Program

Department: Department of Neuroscience
Business Phone: (352) 273-7116
Business Email: ecandelario@ufl.edu

About Eduardo Candelario-Jalil

Dr. Eduardo Candelario-Jalil received his Ph.D. in Pharmacology from the University of Havana, Cuba, in 2002. He did his first postdoctoral training in the Department of Psychiatry at the University of Freiburg, Germany. He studied the signal transduction pathways responsible for cyclooxygenase (COX)-2 upregulation in primary microglial cells and neurons during neuroinflammatory conditions and cerebral ischemia. He joined the University of New Mexico, USA, in 2006 to pursue his second postdoctoral training with Dr. Gary A. Rosenberg and later became a Research Assistant Professor in the Department of Neurology at the University of New Mexico in 2008. After successfully obtaining an R01 grant from the National Institutes of Health (NIH) in 2011, Dr. Candelario-Jalil moved to the University of Florida on a tenure-track faculty position in the Department of Neuroscience, McKnight Brain Institute. In July 2019, Dr. Candelario-Jalil was promoted to Associate Professor with tenure at the University of Florida.

Teaching Profile

Courses Taught
2014,2016-2018,2018-2024
GMS6029 Brain Journal Club
2014-2024
GMS6023 Molecular Neuroscience and Neuropharmacology
2016,2018-2023,2023
GMS7794 Neuroscience Seminar
2019-2021
GMS6705 Functional Human Neuroanatomy
2018,2023-2024
GMS7980 Research for Doctoral Dissertation
2013-2016
GMS6024 Princ Neuroscience 4
2013,2023
GMS7795 Special Topics in Neuroscience
2022-2024
GMS6090 Research in Medical Sciences
2022,2024
GMS6971 Research for Master’s Thesis
2022-2024
GMS7979 Advanced Research
2022-2024
GMS6701 Functional and Comparative Neuroanatomy for Professionals
2023-2024
GMS6905 Independent Studies in Medical Sciences

Research Profile

Dr. Candelario-Jalil’s research interests have been fostered by many years of work in neuropharmacology, biochemistry, and molecular biology. Dr. Candelario-Jalil’s postdoctoral training in Germany and the United States focused upon elucidating the mechanisms underlying the neuroprotective ability of cyclooxygenase-2 (COX-2) inhibitors in experimental animal models of ischemic injury (focal ischemic stroke induced by middle cerebral artery occlusion and global forebrain ischemia). His current research activities are focused on identifying the downstream prostaglandin E2 (PGE2) receptors involved in ischemic brain injury and neuroinflammatory mechanisms responsible for the late opening of the blood-brain barrier following stroke. Other research areas in Dr. Candelario-Jalil’s laboratory include investigating neurovascular effects of adropin, a recently identified peptide, in animal models of ischemic stroke. Moreover, another main project involves the study of the role of bromodomain and extraterminal domain (BET) proteins in the neuroinflammatory response to ischemic stroke.

Dr. Candelario-Jalil directs an active research program with great translational potential, funded by two R01 grants from the NIH. Research is focused on understanding neuroinflammatory mechanisms following ischemic stroke utilizing biochemical, cellular, genetic, pharmacological, and MRI multimodal approaches. As encouraged by the NIH/NINDS Roadmap, this type of translational research is of fundamental importance in accelerating the development of effective stroke therapeutics.

Dr. Candelario-Jalil has authored 72 original peer-reviewed publications, 11 invited review articles, and 3 book chapters. He has made significant contributions to the understanding of neuroinflammatory mechanisms in ischemic stroke, as demonstrated by several research articles published in high-profile and prestigious journals in the field such as Stroke, Journal of Neurochemistry, Journal of Neuroscience, Journal of Cerebral Blood Flow and Metabolism, Journal of Pharmacology & Experimental Therapeutics, and Journal of Neuroinflammation. Dr. Candelario-Jalil’s work has been extensively cited with an h-index of 35.

Areas of Interest
  • Advanced MRI and stroke
  • Blood biomarkers and stroke
  • Neuroimmune interactions in Neurodegenerative diseases
  • Neuroinflammation
  • Protective and preventive measures of cerebrovascular disorders (cerebral ischemia, vascular remodeling and neurological imaging)
  • Stroke recovery
  • cerebral ischemia
Open Researcher and Contributor ID (ORCID)

0000-0003-3631-1989

Publications

2024
Editorial: Reviews in: stroke.
Frontiers in neurology. 15 [DOI] 10.3389/fneur.2024.1364970. [PMID] 38414552.
2023
Neuroprotection by the cannabidiol aminoquinone VCE-004.8 in experimental ischemic stroke in mice
Neurochemistry International. 165 [DOI] 10.1016/j.neuint.2023.105508.
2023
Protective roles of adropin in neurological disease
American Journal of Physiology-Cell Physiology. 324(3):C674-C678 [DOI] 10.1152/ajpcell.00318.2022. [PMID] 36717106.
2023
Receptor-interacting protein kinase 2 (RIPK2) profoundly contributes to post-stroke neuroinflammation and behavioral deficits with microglia as unique perpetrators.
Journal of neuroinflammation. 20(1) [DOI] 10.1186/s12974-023-02907-6. [PMID] 37777791.
2023
Role of Microglia in Psychostimulant Addiction.
Current neuropharmacology. 21(2):235-259 [DOI] 10.2174/1570159X21666221208142151. [PMID] 36503452.
2023
Therapeutic Benefits of Adropin in Aged Mice After Transient Ischemic Stroke via Reduction of Blood-Brain Barrier Damage
Stroke. 54(1):234-244 [DOI] 10.1161/strokeaha.122.039628.
2023
Translating Animal Models of Ischemic Stroke to the Human Condition.
Translational stroke research. 14(6):842-853 [DOI] 10.1007/s12975-022-01082-9. [PMID] 36125734.
2023
Using interleukin-18, Eotaxin-1, and Eotaxin-3 to identify brain injury in neonates with congenital heart disease.
Journal of neuroimmunology. 385 [DOI] 10.1016/j.jneuroim.2023.578239. [PMID] 37976996.
2022
An Unexplored Role for MMP-7 (Matrix Metalloproteinase-7) in Promoting Gut Permeability After Ischemic Stroke
Stroke. 53(10):3238-3242 [DOI] 10.1161/strokeaha.122.040144.
2022
Ischemic Stroke Impacts the Gut Microbiome, Ileal Epithelial and Immune Homeostasis.
iScience. 25(11) [DOI] 10.1016/j.isci.2022.105437. [PMID] 36388972.
2022
Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities
Stroke. 53(5):1473-1486 [DOI] 10.1161/strokeaha.122.036946.
2022
Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated with reduced neuroinflammation and oxidative stress and preservation of blood-brain barrier integrity.
Journal of neuroinflammation. 19(1) [DOI] 10.1186/s12974-022-02533-8. [PMID] 35761277.
2021
Adropin correlates with aging-related neuropathology in humans and improves cognitive function in aging mice
npj Aging and Mechanisms of Disease. 7(1) [DOI] 10.1038/s41514-021-00076-5. [PMID] 34462439.
2021
Altered cellular localisation and expression, together with unconventional protein trafficking, of prion protein, PrPC, in type 1 diabetes
Diabetologia. 64(10):2279-2291 [DOI] 10.1007/s00125-021-05501-8. [PMID] 34274990.
2021
Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.
Experimental neurology. 335 [DOI] 10.1016/j.expneurol.2020.113518. [PMID] 33144066.
2021
Impact of aging and comorbidities on ischemic stroke outcomes in preclinical animal models: A translational perspective.
Experimental neurology. 335 [DOI] 10.1016/j.expneurol.2020.113494. [PMID] 33035516.
2021
Neurovascular protection by adropin in experimental ischemic stroke through an endothelial nitric oxide synthase-dependent mechanism
Redox Biology. 48 [DOI] 10.1016/j.redox.2021.102197. [PMID] 34826783.
2021
Regulation of post-ischemic inflammatory response: A novel function of the neuronal tyrosine phosphatase STEP
Brain, Behavior, and Immunity. 93:141-155 [DOI] 10.1016/j.bbi.2020.12.034. [PMID] 33422638.
2021
Role of BET Proteins in Inflammation and CNS Diseases.
Frontiers in molecular biosciences. 8 [DOI] 10.3389/fmolb.2021.748449. [PMID] 34604312.
2021
Special Issue: Comorbidities in stroke outcomes: Novel therapeutic targets.
Experimental neurology. 340 [DOI] 10.1016/j.expneurol.2021.113641. [PMID] 33689986.
2020
Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19.
Cell metabolism. 32(6):1041-1051.e6 [DOI] 10.1016/j.cmet.2020.11.005. [PMID] 33207244.
2020
Genetic Deletion or Pharmacological Inhibition of Cyclooxygenase-2 Reduces Blood-Brain Barrier Damage in Experimental Ischemic Stroke.
Frontiers in neurology. 11 [DOI] 10.3389/fneur.2020.00887. [PMID] 32973660.
2019
A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer’s disease
Neuropharmacology. 160 [DOI] 10.1016/j.neuropharm.2019.107785.
2019
Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration
International Journal of Molecular Sciences. 20(9) [DOI] 10.3390/ijms20092293. [PMID] 31075861.
2019
Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke
American Journal of Physiology-Cell Physiology. 316(2):C135-C153 [DOI] 10.1152/ajpcell.00136.2018. [PMID] 30379577.
2019
Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke
Neurochemistry International. 127:94-102 [DOI] 10.1016/j.neuint.2019.03.004.
2018
Age-Dependent Decrease in Adropin is Associated with Reduced Levels of Endothelial Nitric Oxide Synthase and Increased Oxidative Stress in the Rat Brain.
Aging and disease. 9(2):322-330 [DOI] 10.14336/AD.2017.0523. [PMID] 29896421.
2018
Protective Effects of L-902,688, a Prostanoid EP4 Receptor Agonist, against Acute Blood-Brain Barrier Damage in Experimental Ischemic Stroke.
Frontiers in neuroscience. 12 [DOI] 10.3389/fnins.2018.00089. [PMID] 29527151.
2018
Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia
Biochemical and Biophysical Research Communications. 497(1):410-415 [DOI] 10.1016/j.bbrc.2018.02.096.
2017
1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) Alters Cell Cycle Progression in Human Neuroblastoma Cell Lines.
Neurotoxicity research. 32(4):649-660 [DOI] 10.1007/s12640-017-9782-1. [PMID] 28721631.
2017
Neuroprotective effects of intrastriatal injection of rapamycin in a mouse model of excitotoxicity induced by quinolinic acid.
Journal of neuroinflammation. 14(1) [DOI] 10.1186/s12974-017-0793-x. [PMID] 28143498.
2017
Post-stroke angiotensin II type 2 receptor activation provides long-term neuroprotection in aged rats.
PloS one. 12(7) [DOI] 10.1371/journal.pone.0180738. [PMID] 28671997.
2017
Selective Inhibition of Janus Kinase 3 Has No Impact on Infarct Size or Neurobehavioral Outcomes in Permanent Ischemic Stroke in Mice.
Frontiers in neurology. 8 [DOI] 10.3389/fneur.2017.00363. [PMID] 28790974.
2017
Spatiotemporal Changes in P-glycoprotein Levels in Brain and Peripheral Tissues Following Ischemic Stroke in Rats.
Journal of experimental neuroscience. 11 [DOI] 10.1177/1179069517701741. [PMID] 28469478.
2017
Sustained Neurological Recovery After Stroke in Aged Rats Treated With a Novel Prostacyclin Analog.
Stroke. 48(7):1948-1956 [DOI] 10.1161/STROKEAHA.117.016474. [PMID] 28588054.
2017
Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A4 analog: Protective mechanisms and long‐term effects on neurological recovery
Brain and Behavior. 7(5) [DOI] 10.1002/brb3.688. [PMID] 28523230.
2016
Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia-like conditions.
Peptides. 81:29-37 [DOI] 10.1016/j.peptides.2016.03.009. [PMID] 27020249.
2016
Neuroprotective effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-β 1-42 induced neurotoxicity and memory impairment.
Scientific reports. 6 [DOI] 10.1038/srep25226. [PMID] 27142962.
2015
Detrimental role of the EP1 prostanoid receptor in blood-brain barrier damage following experimental ischemic stroke.
Scientific reports. 5 [DOI] 10.1038/srep17956. [PMID] 26648273.
2015
Neuroinflammation and Neurodegeneration: Pinpointing Pathological and Pharmacological Targets
BioMed Research International. 2015:1-2 [DOI] 10.1155/2015/487241. [PMID] 26295039.
2014
Neurovascular protection by post-ischemic intravenous injections of the lipoxin A4 receptor agonist, BML-111, in a rat model of ischemic stroke.
Journal of neurochemistry. 129(1):130-42 [DOI] 10.1111/jnc.12607. [PMID] 24225006.
2013
Activation of the Lipoxin A4 Receptor Reduces Infarct Size and Neuroinflammation in a Rat Model of Ischemic Stroke
Journal of Neurochemistry. 125:133-134
2013
Fluorometric immunocapture assay for the specific measurement of matrix metalloproteinase-9 activity in biological samples: application to brain and plasma from rats with ischemic stroke.
Molecular brain. 6 [DOI] 10.1186/1756-6606-6-14. [PMID] 23522154.
2013
Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 33(45):17814-26 [DOI] 10.1523/JNEUROSCI.2346-12.2013. [PMID] 24198371.
2012
Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia.
Journal of neuroinflammation. 9 [DOI] 10.1186/1742-2094-9-2. [PMID] 22214188.
2011
Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment.
Stroke. 42(5):1345-50 [DOI] 10.1161/STROKEAHA.110.600825. [PMID] 21454822.
2011
Tissue inhibitor of metalloproteinases-3 mediates the death of immature oligodendrocytes via TNF-α/TACE in focal cerebral ischemia in mice.
Journal of neuroinflammation. 8 [DOI] 10.1186/1742-2094-8-108. [PMID] 21871134.
2010
Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 30(2):370-80 [DOI] 10.1038/jcbfm.2009.223. [PMID] 19844242.
2010
Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia.
Journal of neurochemistry. 112(1):134-49 [DOI] 10.1111/j.1471-4159.2009.06433.x. [PMID] 19840223.
2010
Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia.
Journal of neuroinflammation. 7 [DOI] 10.1186/1742-2094-7-2. [PMID] 20064241.
2009
A role for cyclooxygenase-1 in beta-amyloid-induced neuroinflammation.
Aging. 1(4):350-3 [PMID] 20157521.
2009
Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia.
Neuroscience. 158(3):983-94 [DOI] 10.1016/j.neuroscience.2008.06.025. [PMID] 18621108.
2009
Increased apparent diffusion coefficients on MRI linked with matrix metalloproteinases and edema in white matter after bilateral carotid artery occlusion in rats.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 29(2):308-16 [DOI] 10.1038/jcbfm.2008.121. [PMID] 18941468.
2009
Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics.
Current opinion in investigational drugs (London, England : 2000). 10(7):644-54 [PMID] 19579170.
2009
Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso-PGF formation in primary glial cells.
Journal of neurochemistry. 109(2):452-64 [DOI] 10.1111/j.1471-4159.2009.05966.x. [PMID] 19200337.
2009
Resveratrol inhibits prostaglandin formation in IL-1beta-stimulated SK-N-SH neuronal cells.
Journal of neuroinflammation. 6 [DOI] 10.1186/1742-2094-6-26. [PMID] 19751497.
2009
Spatiotemporal correlations between blood-brain barrier permeability and apparent diffusion coefficient in a rat model of ischemic stroke.
PloS one. 4(8) [DOI] 10.1371/journal.pone.0006597. [PMID] 19668371.
2008
Cyclooxygenase inhibition in ischemic brain injury.
Current pharmaceutical design. 14(14):1401-18 [PMID] 18537663.
2008
Detrimental effects of tropisetron on permanent ischemic stroke in the rat.
BMC neuroscience. 9 [DOI] 10.1186/1471-2202-9-19. [PMID] 18254974.
2008
Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 28(2):431-8 [PMID] 17700631.
2008
Ischaemic and pharmacological preconditionings protect liver via adenosine and redox status following hepatic ischaemia/reperfusion in rats.
Clinical science (London, England : 1979). 115(2):69-77 [DOI] 10.1042/CS20070415. [PMID] 18307414.
2008
Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in activated rat microglial cells.
Archives of biochemistry and biophysics. 477(2):253-8 [DOI] 10.1016/j.abb.2008.06.017. [PMID] 18621015.
2008
Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences.
Pharmacological research. 57(4):266-73 [DOI] 10.1016/j.phrs.2008.03.003. [PMID] 18439837.
2008
Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2.
Glia. 56(8):844-55 [DOI] 10.1002/glia.20658. [PMID] 18383341.
2008
Serotonin mediates PGE2 overexpression through 5-HT2A and 5-HT3 receptor subtypes in serum-free tissue culture of macrophage-like synovial cells.
Rheumatology international. 28(10):1017-22 [DOI] 10.1007/s00296-008-0564-1. [PMID] 18368410.
2007
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat.
The Journal of pharmacology and experimental therapeutics. 323(2):488-98 [PMID] 17704356.
2007
Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats.
Journal of neurochemistry. 100(4):1108-20 [PMID] 17176264.
2007
Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia.
Journal of neuroinflammation. 4 [PMID] 17927823.
2006
Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production.
Journal of neuroimmunology. 174(1-2):39-51 [PMID] 16529823.
2006
Effects of coffees before and after special treatment procedure on cell membrane potentials in stomach cells.
Methods and findings in experimental and clinical pharmacology. 28(6):369-72 [PMID] 16894406.
2006
Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB.
Journal of neurochemistry. 96(3):680-93 [PMID] 16405508.
2006
Modulation of catecholamine release from rat striatal slices by the fixed combination of aspirin, paracetamol and caffeine.
Pharmacological research. 53(4):391-6 [PMID] 16574428.
2005
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat.
Journal of neuroinflammation. 2(1) [PMID] 15656909.
2005
Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in Purkinje cells of the cerebellum.
Journal of molecular neuroscience : MN. 27(3):303-10 [PMID] 16280600.
2005
Serotonin via 5-HT7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells.
Journal of neurochemistry. 93(3):549-59 [PMID] 15836614.
2005
Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia.
Glia. 51(3):199-208 [PMID] 15800925.
2005
The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway.
Biochemical pharmacology. 70(3):369-80 [PMID] 15922994.
2005
Therapeutic efficacy of ozone in patients with diabetic foot.
European journal of pharmacology. 523(1-3):151-61 [PMID] 16198334.
2004
Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes.
Scandinavian journal of rheumatology. Supplement. 119:28-32 [PMID] 15515409.
2004
Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia-reperfusion.
Liver international : official journal of the International Association for the Study of the Liver. 24(1):55-62 [PMID] 15102001.
2004
Expression of 5-HT3A receptors in cells of the immune system.
Scandinavian journal of rheumatology. Supplement. 119:9-11 [PMID] 15515405.
2004
Tropisetron inhibits serotonin-induced PGE2 release from macrophage-like synovial cells in serum-free tissue culture.
Scandinavian journal of rheumatology. Supplement. 119 [PMID] 15515410.
2004
Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat.
Brain research. 1007(1-2):98-108 [PMID] 15064140.
2003
Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia.
Journal of neurochemistry. 86(3):545-55 [PMID] 12859668.
2003
Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils.
Neuroscience research. 47(2):245-53 [PMID] 14512150.
2003
Effects of nimesulide on kainate-induced in vitro oxidative damage in rat brain homogenates.
BMC pharmacology. 3 [PMID] 12807536.
2003
Effects of pyruvate administration on infarct volume and neurological deficits following permanent focal cerebral ischemia in rats.
Brain research. 990(1-2):1-7 [PMID] 14568323.
2002
Similar protective effect of ischaemic and ozone oxidative preconditionings in liver ischaemia/reperfusion injury.
Pharmacological research. 45(4):333-9 [PMID] 12030798.
2001
“Mangifera indica L. extract (QF808) reduces ischaemia-induced neuronal loss and oxidative damage in the gerbil brain”.
Free radical research. 35(5):465-73 [PMID] 11767405.
2001
Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats.
Pharmacological research. 44(5):391-6 [PMID] 11712870.
2001
Selective vulnerability to kainate-induced oxidative damage in different rat brain regions.
Journal of applied toxicology : JAT. 21(5):403-7 [PMID] 11746182.
2000
Nimesulide limits kainate-induced oxidative damage in the rat hippocampus.
European journal of pharmacology. 390(3):295-8 [PMID] 10708736.

Grants

Jun 2023 ACTIVE
Role of RIPK2 in the neuroinflammatory response to ischemic stroke
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2022 ACTIVE
Neurovascular protection by adropin in acute neural injury from subarachnoid hemorrhage
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2022 ACTIVE
Targeting RIPK2 to modulate neuroinflammation and improve ischemic stroke outcomes
Role: Principal Investigator
Funding: AMER HEART ASSOCIATION
Jan 2022 – Dec 2023
Characterizing the Neuroprotective Effects of Ripk2 Deficiency in Experimental Ischemic Stroke
Role: Other
Funding: AMER HEART ASSOCIATION
Jul 2021 – Jun 2023
Seven tesla preclinical MRI/S scanner for structural, functional and molecular imaging
Role: Other
Funding: NATL INST OF HLTH OD
Jul 2019 ACTIVE
Multi-pronged Approach to Recalibrating the Inflammatory Cascade in Ischemic Stroke with BET blockade
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Apr 2019 – Dec 2020
Degrading BET Proteins is Neuroprotective in Ischemic Stroke
Role: Other
Funding: NATL INST OF HLTH NINDS
Jan 2019 – Mar 2019
BET protein degradation is neuroprotective in ischemic stroke.?
Role: Other
Funding: AMER HEART ASSOCIATION
Sep 2018 – May 2023
Neurovascular Protection by Adropin in Ischemic Stroke
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2018 – Sep 2019
Effects of VCE-004.8, a cannabidiol quinone derivative, on experimental ischemic stroke
Role: Principal Investigator
Funding: EMERALD HEALTH PHARMA
Sep 2017 – Aug 2019
Neurovascular Protection by Adropin in Ischemic Stroke
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2016 – Jun 2018
Prostacyclin Receptor Activation and Neurovascular Protection in Ischemic Stroke
Role: Principal Investigator
Funding: AMER HEART ASSOCIATION
Mar 2014 – Feb 2016
Selexipag Neuroprotection in Ischemic Stroke
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2011 – Dec 2017
Cyclooxygenase-2 Regulation of Blood-Brain Barrier Opening in Ischemic Stroke
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2006 ACTIVE
BRAIN AND SPINAL CORD INJURY RESEARCH
Role: Project Manager
Funding: FL DEPT OF HLTH

Contact Details

Phones:
Business:
(352) 273-7116
Emails:
Addresses:
Business Mailing:
PO Box 100244
GAINESVILLE FL 32610
Business Street:
UNIVERSITY OF FLORIDA ROOM L1-100J
GAINESVILLE FL 326100001